Gamida Cell Stock Net Asset
Gamida Cell fundamentals help investors to digest information that contributes to Gamida Cell's financial success or failures. It also enables traders to predict the movement of Gamida Stock. The fundamental analysis module provides a way to measure Gamida Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gamida Cell stock.
Gamida |
Gamida Cell Company Net Asset Analysis
Gamida Cell's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Gamida Cell Net Asset | 102.19 M |
Most of Gamida Cell's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gamida Cell is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Gamida Cell has a Net Asset of 102.19 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Gamida Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gamida Cell's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gamida Cell could also be used in its relative valuation, which is a method of valuing Gamida Cell by comparing valuation metrics of similar companies.Gamida Cell is currently under evaluation in net asset category among its peers.
Gamida Fundamentals
| Return On Equity | -11.04 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (26.80) % | |||
| Current Valuation | 70.28 M | |||
| Shares Outstanding | 132.64 M | |||
| Shares Owned By Insiders | 11.57 % | |||
| Shares Owned By Institutions | 26.48 % | |||
| Number Of Shares Shorted | 10.96 M | |||
| Price To Earning | (3.97) X | |||
| Price To Book | 117.40 X | |||
| Price To Sales | 6.44 X | |||
| Revenue | 1.78 M | |||
| EBITDA | (70.62 M) | |||
| Net Income | (63 M) | |||
| Cash And Equivalents | 55.06 M | |||
| Cash Per Share | 0.92 X | |||
| Total Debt | 82.94 M | |||
| Current Ratio | 2.57 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (79.12 M) | |||
| Short Ratio | 3.51 X | |||
| Earnings Per Share | (0.82) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 143 | |||
| Beta | 1.03 | |||
| Market Capitalization | 4.34 M | |||
| Total Asset | 102.19 M | |||
| Retained Earnings | (479.83 M) | |||
| Working Capital | 29.34 M | |||
| Current Asset | 56.03 M | |||
| Current Liabilities | 9.55 M | |||
| Net Asset | 102.19 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Gamida Stock
If you are still planning to invest in Gamida Cell check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gamida Cell's history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |